Make Informed Investment Decisions with Affordable Access to Experts
Another Look: Understanding Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by IovanceTicker(s): IOVA
Name: Dr Marco Donia - MD | PhD
Institution: Center for Cancer Immune Therapy, Herlev Hospital
- Associate Professor in Clinical Oncology & Junior Research Group Leader (TIL group) at Herlev Hospital, University of Copenhagen.
- Involved in several aspects of TIL treatment, both translational and clinical research (currently five trials currently open at their site and he is the primary co-supervisor of all.)
- Clinician-scientist with 50% time dedicated to clinical duties; works in an experimental cancer treatment unit and treats around 60 patients/month with cancer immunotherapy – the vast majority with melanoma.
Please describe your clinical practice as it relates to cancer immunotherapies.Added By: c_admin
Can you briefly explain TIL as a mechanism of action?Added By: c_admin
What are your thoughts on Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.